Solifenacin, sold as the brand name Vesicare among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity. It may help with incontinence, urinary frequency, and urinary urgency. Benefits appear similar to other medicat + some more technical info: solifenacin is an orally active competitive muscarinic receptor antagonist with relative selectivity for M3 receptors on detrusor smooth muscle, reducing involuntary bladder contractions. It is usually given once daily in 5 mg and 10 mg oral doses, undergoes hepatic metabolism primarily via CYP3A4, and is eliminated as metabolites in urine and feces. Common adverse effects include dry mouth, constipation, and blurred vision, and caution is advised with strong CYP3A4 inhibitors and in patients with severe hepatic impairment or significant urinary retention.
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin
Parent: Solifenacin/ Solifenacin Succinate
Parent: Solifenacin
Parent: Solifenacin
Manufacturers and regulatory monographs control related compounds and degradation products for solifenacin to low parts-per-hundred levels; typical specifications used in development and registration set limits such that individual known impurities do not exceed 0.1% w/w, any unspecified impurity does not exceed 0.05% w/w, and total impurities generally remain below 0.5% w/w, consistent with ICH Q3A/Q3B principles. Typical related compounds monitored include N-oxide and N-dealkylated metabolites, desalkyl and hydroxy derivatives, process-related synthetic intermediates and starting material residues, and possible ring-opened degradants; residual solvents and elemental impurities are controlled according to ICH guidelines. Routine quality control uses validated HPLC, MS and related methods to quantify these species and ensure batch-to-batch compliance with the stated limits.
Solifenacin is used to treat symptoms of overactive bladder and neurogenic detrusor overactivity, helping reduce urgency, urinary frequency and episodes of incontinence; it is available under brand names including Vesicare.
Solifenacin is not primarily nephrotoxic in recommended doses, but renal impairment can affect drug handling and the risk of anticholinergic adverse effects; dose adjustment or increased monitoring is recommended in moderate to severe renal impairment and use in end stage renal disease should follow specialist guidance.
Many patients notice reduced urinary urgency and frequency within about one week, with maximal symptomatic benefit often observed by two to four weeks of continuous daily dosing.
Yes, solifenacin is an anticholinergic agent; pharmacologically it is a muscarinic receptor antagonist with relative selectivity for the M3 subtype that mediates bladder contraction.
